Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of HRS9531 tablets in healthy subjects
NCT06435676Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Oct 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS9531 in Overweight, obesity and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Number of Adverse Events at 63 days. Started Jun 2024; status: completed.
02
Drugs
HRS9531
03
Conditions
Overweightobesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06435676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435676.